CardioDynamics gains support for Vermed sale
Impedance cardiography (ICG) developer CardioDynamics International of San Diego reported that it is progressing with its shareholders’ approval for the sale of its Vermed business unit. The company reached an agreement to sell the Vermed unit to the subsidiary's management team for a cash purchase price of $8 million in late June this year.
Vermed is a supplier of disposable electrodes and related supplies utilized in electrocardiograph (ECG) and other diagnostic procedures. The division has 85 employees that design, manufacture, and package electrodes from its facility in Bellows Falls, Vt.
CardioDynamics said the decision to sell Vermed will allow it to focus its resources on its proprietary ICG business, which it believes continues to hold the highest growth potential, while maintaining a long-term preferential relationship with Vermed for ICG sensors.
The firm reported that hat the shareholder vote for the sale of Vermed is progressing well with over 50 percent of the necessary shareholder votes (approximately 27 percent of outstanding shares) already cast in favor of the Vermed sale. The ratio of votes received is running in excess of 90 percent for, and less than 10 percent against, the sale of Vermed, according to CardioDynamics.
Vermed is a supplier of disposable electrodes and related supplies utilized in electrocardiograph (ECG) and other diagnostic procedures. The division has 85 employees that design, manufacture, and package electrodes from its facility in Bellows Falls, Vt.
CardioDynamics said the decision to sell Vermed will allow it to focus its resources on its proprietary ICG business, which it believes continues to hold the highest growth potential, while maintaining a long-term preferential relationship with Vermed for ICG sensors.
The firm reported that hat the shareholder vote for the sale of Vermed is progressing well with over 50 percent of the necessary shareholder votes (approximately 27 percent of outstanding shares) already cast in favor of the Vermed sale. The ratio of votes received is running in excess of 90 percent for, and less than 10 percent against, the sale of Vermed, according to CardioDynamics.